Cell therapy companies face many hurdles. I wrote recently about four cell therapy biotechs that have been really struggling. Blogging here at The Niche for more than a dozen years, I’ve seen many companies even go under. That’s bad news for the field, for patients, and for investors. Today I wanted to highlight some cell therapy […]
3 cell therapy companies doing well: Vertex, Vericel, & Regeneron Read More »
I’ve written before about Liz Parrish and her life-extension firm BioViva. Now they appear to have connections with another entity called Integrated Health Systems or IHS, according to a new Wired article. Some of what is going on with IHS and maybe BioViva in Mexico seems extremely risky to me. BioViva, Parrish, and Integrated Health Systems The
Weekly reads: BioViva & life-extension clinic, RMATs, universal cells Read More »
The first time I heard CAR-T cells referred to as a regenerative medicine it made me stop and think. Are CAR-T therapies really a type of regenerative medicine? Generally, CAR-T cells are a designer immune cell therapy. They work by killing cancer cells and that’s what came to mind to me. I don’t tend to
What are CAR-T cells & are they regenerative medicine? Read More »
Cloning is one of those topics that both fascinates and kind of scares people, especially the idea of duplicating people. I regularly cover the topic here on The Niche because stem cell technologies are involved. Also, one form of the process sometimes called “therapeutic cloning” involves embryonic stem cells. Duplicating mammals has now long been
Weekly reads: freeze-dried cloning, FDA signals, stem cell escapees Read More »
Many of you readers know tech guru Peter Diamandis for his great X PRIZE, but he’s also involved in the regenerative medicine world including a new effort called Fountain Life. Teaming up with life coach Tony Robbins and others for Fountain Life raises some red flags for me. What’s in this article Peter Diamandis and
Review of Peter Diamandis Fountain Life clinics: more than stem cell hype? Read More »
The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder. Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021
16 predictions for stem cells & regenerative medicine in 2022 Read More »
If you were to see the phrase ‘Advanced Therapy Medicinal Product’ (ATMP) you might guess, ‘an advanced treatment that is a medicine?’ but you will not get much more from this without doing a lot more homework. What is an ‘Advanced Therapy Medicinal Product’ or ATMP? Whoever decided that cell and gene therapy products should
Cell and gene therapy products: what is an ATMP? Read More »
What are embryonic stem cells and how do we scientists obtain them? My lab here at UC Davis School of Medicine has been doing research on embryonic stem cells for more than 14 years. You’ve come to the right place for expert answers on these very intriguing cells. What’s in this article Where do embryonic
What are embryonic stem cells & where do they come from? Read More »
Each year I metaphorically try to look into a crystal ball for stem cell predictions for the coming year and I did so for 2020, but the COVID-19 pandemic threw a monkey wrench into my predictions. It actually kind of blew some up. It also raised some interesting questions and dilemmas. For instance, do many
Grading my 20 stem cell predictions for 2020 Read More »
IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for
Overview of IPS cell prospects for clinical impact Read More »